125 related articles for article (PubMed ID: 15054116)
1. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.
Whiteside GT; Harrison JE; Pearson MS; Chen Z; Fundytus ME; Rotshteyn Y; Turchin PI; Pomonis JD; Mark L; Walker K; Broglé KC
J Pharmacol Exp Ther; 2004 Aug; 310(2):793-9. PubMed ID: 15054116
[TBL] [Abstract][Full Text] [Related]
2. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.
Valenzano KJ; Miller W; Chen Z; Shan S; Crumley G; Victory SF; Davies E; Huang JC; Allie N; Nolan SJ; Rotshteyn Y; Kyle DJ; Broglé K
J Pharmacol Exp Ther; 2004 Aug; 310(2):783-92. PubMed ID: 15054115
[TBL] [Abstract][Full Text] [Related]
3. The role of central and peripheral mu opioid receptors in inflammatory pain and edema: a study using morphine and DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid).
Whiteside GT; Boulet JM; Walker K
J Pharmacol Exp Ther; 2005 Sep; 314(3):1234-40. PubMed ID: 15937151
[TBL] [Abstract][Full Text] [Related]
4. The novel compound (+/-)-1-[10-((E)-3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined mu-opioid receptor agonist and monoamine reuptake inhibitor tramadol.
Munro G; Baek CA; Erichsen HK; Nielsen AN; Nielsen EØ; Scheel-Kruger J; Weikop P; Peters D
Neuropharmacology; 2008 Feb; 54(2):331-43. PubMed ID: 18037451
[TBL] [Abstract][Full Text] [Related]
5. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
6. Peripherally mediated antinociception of the mu-opioid receptor agonist 2-[(4,5alpha-epoxy-3-hydroxy-14beta-methoxy-17-methylmorphinan-6beta-yl)amino]acetic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation.
Bileviciute-Ljungar I; Spetea M; Guo Y; Schütz J; Windisch P; Schmidhammer H
J Pharmacol Exp Ther; 2006 Apr; 317(1):220-7. PubMed ID: 16339394
[TBL] [Abstract][Full Text] [Related]
7. The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model of rats.
Wang JY; Zhao M; Yuan YK; Fan GX; Jia H; Tang JS
Neuroscience; 2006; 138(4):1319-27. PubMed ID: 16472929
[TBL] [Abstract][Full Text] [Related]
8. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
Schiene K; De Vry J; Tzschentke TM
J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
[TBL] [Abstract][Full Text] [Related]
9. Local peripheral antinociceptive effects of 14-O-methyloxymorphone derivatives in inflammatory and neuropathic pain in the rat.
Obara I; Makuch W; Spetea M; Schütz J; Schmidhammer H; Przewlocki R; Przewlocka B
Eur J Pharmacol; 2007 Mar; 558(1-3):60-7. PubMed ID: 17204264
[TBL] [Abstract][Full Text] [Related]
10. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity.
DeHaven-Hudkins DL; Burgos LC; Cassel JA; Daubert JD; DeHaven RN; Mansson E; Nagasaka H; Yu G; Yaksh T
J Pharmacol Exp Ther; 1999 Apr; 289(1):494-502. PubMed ID: 10087042
[TBL] [Abstract][Full Text] [Related]
11. Nociceptive sensitivity and opioid antinociception and antihyperalgesia in Freund's adjuvant-induced arthritic male and female rats.
Cook CD; Nickerson MD
J Pharmacol Exp Ther; 2005 Apr; 313(1):449-59. PubMed ID: 15608071
[TBL] [Abstract][Full Text] [Related]
12. Roles of different subtypes of opioid receptors in mediating the ventrolateral orbital cortex opioid-induced inhibition of mirror-neuropathic pain in the rat.
Zhao M; Wang JY; Jia H; Tang JS
Neuroscience; 2007 Feb; 144(4):1486-94. PubMed ID: 17184926
[TBL] [Abstract][Full Text] [Related]
13. JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependence.
Codd EE; Carson JR; Colburn RW; Stone DJ; Van Besien CR; Zhang SP; Wade PR; Gallantine EL; Meert TF; Molino L; Pullan S; Razler CM; Dax SL; Flores CM
J Pharmacol Exp Ther; 2009 Apr; 329(1):241-51. PubMed ID: 19151246
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
15. mu- but not delta- and kappa-opioid receptors in the ventrolateral orbital cortex mediate opioid-induced antiallodynia in a rat neuropathic pain model.
Zhao M; Wang JY; Jia H; Tang JS
Brain Res; 2006 Mar; 1076(1):68-77. PubMed ID: 16476416
[TBL] [Abstract][Full Text] [Related]
16. Spinal administration of a delta opioid receptor agonist attenuates hyperalgesia and allodynia in a rat model of neuropathic pain.
Holdridge SV; Cahill CM
Eur J Pain; 2007 Aug; 11(6):685-93. PubMed ID: 17175187
[TBL] [Abstract][Full Text] [Related]
17. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
[TBL] [Abstract][Full Text] [Related]
18. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
[TBL] [Abstract][Full Text] [Related]
19. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
Chen SR; Pan HL
J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
[TBL] [Abstract][Full Text] [Related]
20. Spinal mu-opioid receptor expression and hyperalgesia with dexamethasone in chronic adjuvant-induced arthritis in rats.
Zaringhalam J; Manaheji H; Mghsoodi N; Farokhi B; Mirzaiee V
Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1309-15. PubMed ID: 18671722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
